276 related articles for article (PubMed ID: 35493444)
1. Bioactive Lipids as Chronic Myeloid Leukemia's Potential Biomarkers for Disease Progression and Response to Tyrosine Kinase Inhibitors.
de Almeida FC; Berzoti-Coelho MG; Toro DM; Cacemiro MDC; Bassan VL; Barretto GD; Garibaldi PMM; Palma LC; de Figueiredo-Pontes LL; Sorgi CA; Faciolli LH; Gardinassi LG; de Castro FA
Front Immunol; 2022; 13():840173. PubMed ID: 35493444
[TBL] [Abstract][Full Text] [Related]
2. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
[TBL] [Abstract][Full Text] [Related]
5. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
6. Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
Branford S; Fernandes A; Shahrin N; Maqsood M; Shanmuganathan N; Wadham C
J Natl Compr Canc Netw; 2024 Feb; 22(1):. PubMed ID: 38394774
[TBL] [Abstract][Full Text] [Related]
7. Loss of G0/G1 switch gene 2 (G0S2) promotes disease progression and drug resistance in chronic myeloid leukaemia (CML) by disrupting glycerophospholipid metabolism.
Gonzalez MA; Olivas IM; Bencomo-Alvarez AE; Rubio AJ; Barreto-Vargas C; Lopez JL; Dang SK; Solecki JP; McCall E; Astudillo G; Velazquez VV; Schenkel K; Reffell K; Perkins M; Nguyen N; Apaflo JN; Alvidrez E; Young JE; Lara JJ; Yan D; Senina A; Ahmann J; Varley KE; Mason CC; Eide CA; Druker BJ; Nurunnabi M; Padilla O; Bajpeyi S; Eiring AM
Clin Transl Med; 2022 Dec; 12(12):e1146. PubMed ID: 36536477
[TBL] [Abstract][Full Text] [Related]
8. The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.
Crisan AM; Coriu D; Arion C; Colita A; Jardan C
J Med Life; 2015; 8(4):502-8. PubMed ID: 26664479
[TBL] [Abstract][Full Text] [Related]
9. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
[TBL] [Abstract][Full Text] [Related]
10. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
12. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy.
Rodriguez J; Iniguez A; Jena N; Tata P; Liu ZY; Lander AD; Lowengrub J; Van Etten RA
Elife; 2023 Apr; 12():. PubMed ID: 37115622
[TBL] [Abstract][Full Text] [Related]
13. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
[TBL] [Abstract][Full Text] [Related]
14. Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
Kim T; Tyndel MS; Zhang Z; Ahn J; Choi S; Szardenings M; Lipton JH; Kim HJ; Kim Dong Hwan D
Leuk Res; 2017 Aug; 59():142-148. PubMed ID: 28667884
[TBL] [Abstract][Full Text] [Related]
15. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Zhang WW; Cortes JE; Yao H; Zhang L; Reddy NG; Jabbour E; Kantarjian HM; Jones D
J Clin Oncol; 2009 Aug; 27(22):3642-9. PubMed ID: 19506164
[TBL] [Abstract][Full Text] [Related]
16. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing and managing advanced chronic myeloid leukemia.
Deininger MW
Am Soc Clin Oncol Educ Book; 2015; ():e381-8. PubMed ID: 25993200
[TBL] [Abstract][Full Text] [Related]
18. Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.
Adnan-Awad S; Kankainen M; Mustjoki S
Leuk Lymphoma; 2021 Sep; 62(9):2064-2078. PubMed ID: 33944660
[TBL] [Abstract][Full Text] [Related]
19. CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1
Schneeweiss-Gleixner M; Byrgazov K; Stefanzl G; Berger D; Eisenwort G; Lucini CB; Herndlhofer S; Preuner S; Obrova K; Pusic P; Witzeneder N; Greiner G; Hoermann G; Sperr WR; Lion T; Deininger M; Valent P; Gleixner KV
EBioMedicine; 2019 Dec; 50():111-121. PubMed ID: 31761618
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
